Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

References

• Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (Trastuzumab) for metastatic breast cancer. A model based cost effectiveness analysis. Ann Oncol 2005; 16: 909–14
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer; correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel c-erbB–related gene in a human mammary carcinoma. Science 1985; 229: 974–6
   PubMed Web of Science ®Google Scholar
• Seshadri R, Firgaira EA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11: 1936–42
   PubMed Web of Science ®Google Scholar
• Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53: 4960–70
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Di Leo A, Hamilton A. Her2: A predictive factor ready to use in the daily management of breast cancer patient?. Eur J Cancer 2002; 36: 1755–61
   Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61: 37–42
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. First-line single-agent Herceptin (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001; 37: 25–9
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a.monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maianinchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265–74
   PubMed Web of Science ®Google Scholar
• Romond RH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM 2005; 353: 1673–84
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005; 353: 1659–72
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM 2006; 354: 809–20
   PubMed Web of Science ®Google Scholar
• Drummond, MF, O'Brian, B, Stoddart, GL, Torrance, GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, 2nd ed. Oxford, New York, Toronto: Oxford University Press; 1997.
   Google Scholar
• Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther 1998; 20: 1194–202
   PubMedGoogle Scholar
• Norum J, Holtmon M. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer. Is it cost-effective?. Acta Oncol 2005; 44: 735–41
   PubMed Web of Science ®Google Scholar
• De Laurentiis, M, Cancello, G, Zinno, L, Montagna, E, Malomi, M, Esposito, A, et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl. 4):iv7–iv13.
   PubMed Web of Science ®Google Scholar
• Slamon, D, Eiermann, W, Robert, N, Pienkowski, T, Martin, M, Pawlicki, M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. BCIRG 006 study. San Antonio Breast Cancer Symposium. Abstr. 2005; 1069( www.abstracts.com/sabcs05): 2view
   Google Scholar
• Bonadonna, G, Moliterni, A, Zambetti, M, Daidone, MG, Pilotti, S, Gianni, L, et al. 30 years’ follow-up of randomised studies of adjuvant CMF in operable breast cancer. Cohort study. BMJ 2005;330:217, Epub.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001; 98: 10869–74
   PubMed Web of Science ®Google Scholar
• Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer. Is it cost effective?. Acta Oncol 2000; 39: 33–9
   PubMed Web of Science ®Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation; the ongoing debate. Value Health 2004; 7: 397–401
   PubMed Web of Science ®Google Scholar
• The National Health Administration. The tariff of public out-patient treatment valid from January 1st 2005. Oslo: The National Health Administration; 2004.
   Google Scholar
• Department of Health and Care Services. Information about Diagnosis Related Groups 2005. Oslo; Department of Health and Care Services: 2005.
   Google Scholar
• Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky M, et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy driven acceleration of the metastaic process. Ann Oncol 2005; 16: 1449–57
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tokuda Y, Saito Y, Ohta M, Tajima T. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 2003; 33: 514–7
   PubMed Web of Science ®Google Scholar
• Nistico C, Garufi C, Milella M, Vaccaro A, D'Ottavio AM, Fabi A, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000; 59: 223–9
   PubMed Web of Science ®Google Scholar
• Verma S, Trudeau M, Dranitsaris G, Clemons M, Joy AA, MacKey JR. What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005; 23: 6260
   PubMedGoogle Scholar
• Belgian Society for Pharmacoepidemiology. A proposal for methodological guidelines for economic evaluation of pharmaceuticals. Brussels: Belgian Society for Pharmacoepidemiology (BESPE); 1995.
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8
   PubMed Web of Science ®Google Scholar
• Hjelmgren J, Berggren F, Andersson F. Health economic guidelines – similarities, differences and some implications. Value Health 2001; 4: 225–50
   PubMedGoogle Scholar
• Norum J, Olsen JA, Wist EA. Lumpectomy or mastectomy? Is breast conserving surgery too expensive?. Breast Cancer Res Treat 1997; 45: 7–14
   PubMedGoogle Scholar
• Mols F, Vingerhoets JJM, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors. A systematic review. Eur J Cancer 2005; 41: 2613–9
   PubMed Web of Science ®Google Scholar
• Ministry of Finance. A guide to societal economic analysis. Oslo: Ministry of Finance; 2005. ( http://odin.dep.no/fin/norsk/dok/regelverk/retninglinjer/007021-990004/dok–bn.html)
   Google Scholar
• McLaren EH. Adjuvant trastuzumab for breast cancer. BMJ 2005; 331: 1203
   PubMedGoogle Scholar
• Hillner, BE.. Clinical and cost-effectiveness implications of the adjuvant trastuzumab in HER2+ breast cancer trials. San Antonio Breast Cancer Symposium. Abstr. 2005; 5040( www.abstracts.com/sabcs05): 2view
   Google Scholar
• Kondro W, Sibbald B. Patient demand and politics push Herceptin forward. CMAJ 2005; 173: 347–8
   PubMedGoogle Scholar
• Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. We need to ensure that equity exists for access to effective and expensive treatments. BMJ 2005; 331: 1035–6
   PubMedGoogle Scholar
• Mayor S. Primary care trust reverse decision not to fund trastuzumab. BMJ 2005; 331: 1162
   Google Scholar
• Ragaz, J, Spinelli, JJ.. Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa). San Antonio Breast Cancer Symposium. Abstr. 2005; 2029( www.abstracts.com/sabcs05): 2view
   Google Scholar
• Norum J. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opin Pharmacother 2006; 7: 1617–25
   PubMed Web of Science ®Google Scholar
• The Norwegian knowledge centre for the health services.Adjuvant therapy with trastuzumab in early stage breast cancer – An health economic analysis The Norwegian knowledge centre for the health services, Report no 18, Oslo, 2006 ( http://www.kunnskapssenteret.no/filer/Rapport1806_Herceptin_helseok.pdf)
   Google Scholar
• Danish national board of health. Trastuzumab (Herceptin) in adjuvant treatment of early breast cancer following surgery. Preliminary report. Med Teknol kræftlegemidler. 2005;1:1–21 ( http://www.sst.dk/publ/Publ2005/CEMTV/Laegemidler/Trastuzumab_syntese.pdf)
   Google Scholar
• Editorial. Herceptin and early breast cancer. A moment for caution. Lancet 2005; 366: 1673
   PubMedGoogle Scholar
• Neyt, M, Albrecht, J, Cocquyt, C. An economic evaluation of Herceptin in adjuvant setting. The breast cancer international research group 006 trial. Ann Oncol 2005; doi: 10.1093/annonc/mdj101.
   Google Scholar
• Nadler ES, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value?. Proc Am Soc Clin Oncol 2005; 23: a6011
   Web of Science ®Google Scholar